[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1330741110.png) @TomSilver39 Tom Silver

Tom Silver posts on X about $cytk, $incy, $regn, nrix the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1330741110/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1330741110/c:line/m:interactions.svg)

- X Week XXXXXX +300%
- X Month XXXXXX -XX%
- X Months XXXXXXX -XX%
- X Year XXXXXXXXX +51%

### Mentions: X [#](/creator/twitter::1330741110/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1330741110/c:line/m:posts_active.svg)

- X Week XX no change
- X Month XX +3.90%
- X Months XX -XXXX%
- X Year XXX +74%

### Followers: XXXXX [#](/creator/twitter::1330741110/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1330741110/c:line/m:followers.svg)

- X Week XXXXX +0.21%
- X Month XXXXX +1.40%
- X Months XXXXX +8.90%
- X Year XXXXX +23%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1330741110/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1330741110/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1330741110/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXXX% [finance](/list/finance)  XXXXX% [countries](/list/countries)  XXXX% [cryptocurrencies](/list/cryptocurrencies)  XXXX%

**Social topic influence**
[$cytk](/topic/$cytk) 11.11%, [$incy](/topic/$incy) 11.11%, [$regn](/topic/$regn) 11.11%, [nrix](/topic/nrix) 5.56%, [$oabi](/topic/$oabi) 5.56%, [$absi](/topic/$absi) 5.56%, [$nrix](/topic/$nrix) 5.56%, [$kymr](/topic/$kymr) 5.56%, [$ewtx](/topic/$ewtx) 5.56%, [$kura](/topic/$kura) XXXX%

**Top accounts mentioned or mentioned by**
[@biopharmiq](/creator/undefined) [@celocal](/creator/undefined) [@usfda](/creator/undefined) [@wsj](/creator/undefined) [@willy1773](/creator/undefined) [@bioinvestor24](/creator/undefined) [@artsstocks](/creator/undefined)

**Top assets mentioned**
[Cytokinetics Inc. (CYTK)](/topic/$cytk) [Incyte Corporation (INCY)](/topic/$incy) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Kymera Therapeutics, Inc. Common Stock (KYMR)](/topic/$kymr) [Edgewise Therapeutics, Inc. Common Stock (EWTX)](/topic/$ewtx) [Nuvalent, Inc. Class A Common Stock (NUVL)](/topic/$nuvl) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Merus N.V. Common Shares (MRUS)](/topic/$mrus) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Neurocrine Biosciences, Inc. (NBIX)](/topic/$nbix) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [United Community Banks, Inc. (UCB)](/topic/$ucb) [Acadia Pharmaceuticals Inc. (ACAD)](/topic/$acad) [One Cash (ONC)](/topic/$onc) [Amgen, Inc. (AMGN)](/topic/$amgn) [Exelixis Inc (EXEL)](/topic/$exel) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)](/topic/$rytm) [Blueprint Medicines Corporation (BPMC)](/topic/$bpmc) [Celldex Therapeutics, Inc (CLDX)](/topic/$cldx)
### Top Social Posts [#](/creator/twitter::1330741110/posts)
---
Top posts by engagements in the last XX hours

"Trust:" 2H2025 - SMID Catalyst Preview: $KYMR $NRIX $CYTK $EWTX $ABSI $OABI: KYMR: KT-621 Ph1b AD data (4Q25E); looking for oral dupi-like activity in disease population; NRIX: Await Ph1 updates in expansion cohorts and confirmatory trial designs for bexo; Ph1 clinical updates for NX-2127 and NX-1607; CYTK: Ph3 MAPLE data (ESC25) could help formulary positioning; +ve afi label vs. mava could lead to further differentiation (PDUFA Dec 26); EWTX: A deepening of LVOT-G response for CIRRUS Part D data (2H25) could support share upside; ABSI: ABS-201 Ph1 POC data to validate superior"  
![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1330741110.png) [@TomSilver39](/creator/x/TomSilver39) on [X](/post/tweet/1945742980314517679) 2025-07-17 07:10:51 UTC 9515 followers, 1918 engagements


"Leerink;" #esmo25 First Glimpse: $GMAB $IMTX $KURA $NUVL $IDYA $INCY $MRUS $GMAB Rina-S (rinatabart sesutecan folate receptor alpha FR antibody drug conjugate ADC) in 2L+ endometrial cancer (#1121P). $IMTX IMA203 (PRAME TCR T-cell therapy Gen 1) in previously treated advanced or metastatic uveal melanoma in an oral presentation (#1600O). IMA203 is also being evaluated in the Phase III SUPRAME study in PD1-refractory cutaneous melanoma with an interim analysis expected in 1Q26. In addition to this ESMO update that may provide further validation for IMA203 we continue to expect Phase I data"  
![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1330741110.png) [@TomSilver39](/creator/x/TomSilver39) on [X](/post/tweet/1948995604157509888) 2025-07-26 06:35:37 UTC 9518 followers, 2160 engagements


"JPM:" $VKTX 2Q25 Review: Qtr Highlighted by Progress in Both Ongoing SubQ/Oral VK2735 Trials.an attractive pure-play option to invest in the obesity market oppty with somewhat derisked mid-late stage assets. Remain OW.""  
![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1330741110.png) [@TomSilver39](/creator/x/TomSilver39) on [X](/post/tweet/1948210471498142004) 2025-07-24 02:35:47 UTC 9519 followers, 31.1K engagements


"Workers in Las Vegas have a problem; Tourist-dependent destination is having a slow year and its one that no tax on tips cant fix via @WSJ"  
![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1330741110.png) [@TomSilver39](/creator/x/TomSilver39) on [X](/post/tweet/1949288349317095581) 2025-07-27 01:58:53 UTC 9518 followers, 1184 engagements


"$CYTK Catalysts: 1) August XX - Detailed Ph3 MAPLE-HCM results: Aficamten vs Metoprolol in oHCM; 2) 2H25: Potential approval of aficamten in China; 3) Dec XX 2025: Aficamten PDUFA in oHCM; 4) 1H26: Potential EMA approval of aficamten; 5) 1H26: Topline results for ACACIA-HCM"  
![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1330741110.png) [@TomSilver39](/creator/x/TomSilver39) on [X](/post/tweet/1947357511989821743) 2025-07-21 18:06:25 UTC 9512 followers, 2162 engagements


"Cowen:" TD Cowen's top ideas for Q3:25 performance include $NBIX $BBIO $UCB $RAPP $ACAD $URGN and $ONC. Companies we believe are most likely to post Q2 sales/earnings in excess of consensus include $ADAP $AMGN $ARGX $ARQT $ASND $BBIO $EXEL $GILD $IMCR $MDGL $ONC $NBIX $REGN $RYTM $SNDX $UCB and $VRCA.Sentiment toward biotech stocks improved through Q2 and enters H2 above the nadir reached in the spring. Though investors are still worried about the headwinds from Washington the worst fears have not borne out. Our analysis suggests generally solid Q2 financial performance. We are hopeful that"  
![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1330741110.png) [@TomSilver39](/creator/x/TomSilver39) on [X](/post/tweet/1948416081217171561) 2025-07-24 16:12:48 UTC 9518 followers, 3208 engagements


"Cowen:" SCRATCHING THE URTICARIA OPPORTUNITY IN AUTOIMMUNE; Top picks: $BPMC $CLDX $INCY $JSPR $REGN. Chronic urticaria is an autoimmune condition characterized by intensely itchy hives and/or angioedema (which can be spontaneous or induced by specific triggers) that affects millions of individuals and represents an underappreciated opportunity for investors. KOLs emphasize that CSU is not a benign disease but a debilitating chronic condition (lasting 5-7 years on average) characterized by severe and unpredictable pain/itch with up to XX% of patients also experiencing recurrent angioedema"  
![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1330741110.png) [@TomSilver39](/creator/x/TomSilver39) on [X](/post/tweet/1925196416173113538) 2025-05-21 14:26:08 UTC 9517 followers, 4177 engagements